Description of Invention: Despite mass vaccination, reported pertussis cases have increased in the United States and other parts of the world, probably because of increased awareness, improved diagnostic means, and waning vaccine-induced immunity among adolescents and adults. Licensed vaccines do not kill the organism directly; the addition of a component inducing bactericidal antibodies would improve vaccine efficacy. This application claims Bordetella pertussis and Bordetella bronchiseptica LPS-derived core oligosaccharide (OS) protein conjugates. B. pertussis and B. bronchiseptica core OS were bound to aminooxylated BSA via their terminal Kdo residues. The two conjugates induced similar anti-B. pertussis LPS IgG levels in mice. Conjugate-induced antisera were bactericidal against B. pertussis.
Applications:
Pertussis prophylactic conjugate vaccine.
Use of vaccine to generate neutralizing antibodies.
Advantages: Conjugates are easy to prepare and standardize; added to a recombinant pertussis toxoid, they may induce antibacterial and antitoxin immunity.
Development Status:
Pre-clinical
In vitro data available
In vivo data available (animal)
Inventors: Joanna Kubler-kielb (NICHD) Rachel Schneerson (NICHD) John B Robbins (NICHD) Ariel Ginzberg (NICHD) Teresa Lagergard (NICHD)
Collaborative Research Opportunity: The NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize vaccines against pertussis. For collaboration opportunities, please contact Joseph Conrad, III, Ph.D. at jmconrad@mail.nih.gov .
For Licensing Information Please Contact: Peter Soukas J.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 14, Rockville, MD 20852-3804 United States Email: soukasp@mail.nih.gov Phone: 301-435-4646 Fax: 301-402-0220
Description of Invention:
Despite mass vaccination, reported pertussis cases have increased in the United States and other parts of the world, probably because of increased awareness, improved diagnostic means, and waning vaccine-induced immunity among adolescents and adults. Licensed vaccines do not kill the organism directly; the addition of a component inducing bactericidal antibodies would improve vaccine efficacy. This application claims Bordetella pertussis and Bordetella bronchiseptica LPS-derived core oligosaccharide (OS) protein conjugates. B. pertussis and B. bronchiseptica core OS were bound to aminooxylated BSA via their terminal Kdo residues. The two conjugates induced similar anti-B. pertussis LPS IgG levels in mice. Conjugate-induced antisera were bactericidal against B. pertussis.
Applications:
Advantages:
Conjugates are easy to prepare and standardize; added to a recombinant pertussis toxoid, they may induce antibacterial and antitoxin immunity.
Development Status:
Inventors:
Joanna Kubler-kielb (NICHD)
Rachel Schneerson (NICHD)
John B Robbins (NICHD)
Ariel Ginzberg (NICHD)
Teresa Lagergard (NICHD)
Patent Status:
HHS, Reference No. E-006-2011/0
US, Application No. 61/438,190 filed 31 Jan 2011
Related Technologies:
US, Application No. 12/309,428 filed 16 Jan 2009, Reference No. E-183-2005/0
US, Application No. 60/832,448 filed 21 Jul 2006, Reference No. E-183-2005/0
PCT, Application No. PCT/US2007/016373 filed 18 Jul 2007, Reference No. E-183-2005/0
Relevant Publication:
Collaborative Research Opportunity:
The NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize vaccines against pertussis. For collaboration opportunities, please contact Joseph Conrad, III, Ph.D. at jmconrad@mail.nih.gov .
For Licensing Information Please Contact:
Peter Soukas J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 14,
Rockville, MD 20852-3804
United States
Email: soukasp@mail.nih.gov
Phone: 301-435-4646
Fax: 301-402-0220
Ref No: 2289
Updated: 07/2011